Targeted engineered extracellular vesicle-loaded injectable hydrogel as well as preparation method and application thereof

By targeting the GelMA hydrogel loaded with extracellular vesicles, the stability and compatibility of injectable hydrogels in cardiac treatment are solved, and efficient repair and continuous treatment effects of cardiac ischemia and reperfusion injury are achieved. .

CN118975977AActive Publication Date: 2024-11-19SHANGHAI UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411105636.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-11-19
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

The existing injectable hydrogels have problems such as insufficient gelation stability, poor biocompatibility and uncontrollable mechanical properties in the treatment of cardiovascular diseases, making it difficult to effectively repair cardiac ischemia and reperfusion injury.

Method used

Using GelMA hydrogel targeted engineered extracellular vesicles loading, the injectable water targeted engineered extracellular vesicles was prepared by transforming the miR222 gene into extracellular vesicles and combining with the targeted polypeptide. The gel, loaded in combination with the GelMA precursor, forms a hydrogel with high stability, good biocompatibility and adjustable mechanical properties, for pericardial injection to repair cardiac ischemia and reperfusion injury.

Benefits of technology

It has achieved minimally invasive injection into the pericardial cavity to form a cardiac patch, significantly improving cardiac ischemia and reperfusion injury, with good biocompatibility and body adaptability, and can regulate the release rate of targeted engineered extracellular vesicles, and continuously Repairing heart damage simplifies the production process and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118975977A_ABST
    Figure CN118975977A_ABST
Patent Text Reader

Abstract

The invention relates to injectable hydrogel loaded by targeted engineered extracellular vesicles as well as a preparation method and application of the injectable hydrogel, and belongs to biomedical engineering. The invention provides injectable hydrogel loaded by targeted engineered extracellular vesicles. The injectable hydrogel loaded by the targeted engineered extracellular vesicles is GelMA hydrogel loaded by ischemia-targeted miR222 engineered extracellular vesicles, and the injectable hydrogel loaded by the targeted engineered extracellular vesicles is an injectable hydrogel loaded by the ischemia-targeted miR222 engineered extracellular vesicles. The ischemia targeting miR222 engineered extracellular vesicle overexpresses miR222, and the surface is modified with targeting polypeptide. The injectable hydrogel loaded by the targeted engineered extracellular vesicles can be injected into a pericardial cavity in a minimally invasive manner to form a heart patch and improve heart ischemia reperfusion injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedical engineering, and in particular relates to an injectable hydrogel loaded with targeted engineered extracellular vesicles, and a preparation method and application thereof. Background Art

[0002] The morbidity and mortality of cardiovascular disease (CVD) have been on an upward trend for many years. Although the condition of CVD patients has been alleviated through conservative drug treatment and surgical treatment, the re-hospitalization rate and mortality rate remain at a high recurrence rate. Various heart diseases, including acute myocardial infarction (MI), pathological myocardial hypertrophy, ischemia-reperfusion injury (IRI) and heart failure (HF), continue to be at a high risk, seriously threatening human life and becoming a major public health topic for the whole society.

[0003] Ischemia and hypoxia in the coronary arteries lead to the death of cardiomyocytes (CMs), thus inducing cardiac dysfunction. In clinical practice, thrombolysis, percutaneous coronary intervention, and transplantation can restore ischemia-reperfusion injury in the coronary arteries. However, these methods are prone to cause greater trauma to the heart, resulting in secondary damage, and there is a possibility of recurrence of cardiac dysfunction. Once perfusion occurs, pressure overload (Piezo1) and highly reactive oxygen species (ROS) will cause secondary damage to CMs due to the loss of mechanical protection in the cardiac microenvironment.

[0004] Regenerative cardiac therapy uses biocompatible materials and biological tissues combined with nucleic acids, proteins and living cells, and is considered to be an ideal strategy for providing personalized precision treatment for severe ischemia-reperfusion injury. Biofunctional hydrogels are widely used in cardiac regeneration and repair, and injectable hydrogels may be used to treat cardiovascular diseases in a minimally invasive manner. At present, injectable hydrogels have shortcomings such as insufficient gelation stability, poor biocompatibility and uncontrollable mechanical properties, making it difficult to achieve treatment and repair of organs such as the heart in vivo. Summary of the invention

[0005] The purpose of the present invention is to provide an injectable hydrogel loaded with targeted engineered extracellular vesicles. The injectable hydrogel loaded with targeted engineered extracellular vesicles of the present invention has high stability, good biocompatibility, and adjustable mechanical properties, and can be injected into the pericardial cavity in a minimally invasive manner to form a cardiac patch and improve cardiac ischemia-reperfusion injury.

[0006] The present invention provides an injectable hydrogel loaded with targeted engineered extracellular vesicles, wherein the injectable hydrogel loaded with targeted engineered extracellular vesicles is a GelMA hydrogel loaded with ischemia-targeted miR222 engineered extracellular vesicles; the ischemia-targeted miR222 engineered extracellular vesicles overexpress miR222 and are surface-modified with a targeting polypeptide; the amino acid sequence of the targeting polypeptide is shown in SEQ ID NO.1.

[0007] Preferably, the average Young's modulus of the targeted engineered extracellular vesicle-loaded injectable hydrogel is 5 to 30 kPa (14 to 18 kPa).

[0008] The present invention also provides a method for preparing the injectable hydrogel loaded with targeted engineered extracellular vesicles according to the above technical solution, comprising the following steps:

[0009] GelMA precursor was prepared using type A gelatin and methacrylic anhydride as raw materials;

[0010] Human umbilical cord mesenchymal stem cells are used as raw materials to extract and obtain HUC-MSC-derived extracellular vesicles; miR222 gene is transformed into HUC-MSC-derived extracellular vesicles to obtain miR222-engineered extracellular vesicles; the targeted peptide is mixed with DOPE-NHS solution to obtain a peptide linker, which is then concentrated and mixed with the miR222-engineered extracellular vesicles to obtain targeted engineered extracellular vesicles;

[0011] The GelMA precursor, the photoinitiator and the targeted engineered extracellular vesicles are mixed and loaded to obtain an injectable hydrogel loaded with the targeted engineered extracellular vesicles.

[0012] Preferably, the preparation of the GelMA precursor comprises the following steps: dissolving type A gelatin in PBS to obtain a gelatin solution, and adding methacrylic anhydride dropwise to the gelatin solution to react to obtain the GelMA precursor.

[0013] Preferably, the mass ratio of type A gelatin to the volume ratio of methacrylic anhydride is 5 g: (0.2-5) mL.

[0014] Preferably, during the loading process, PBS is used as a solvent to prepare the reaction solution, the weight ratio of GelMA precursor to photoinitiator is (2-8):100, and each 20 μL reaction solution contains 1×10 targeted engineered extracellular vesicles. 8 ~5×10 9 indivual.

[0015] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical scheme or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical scheme in the preparation of drugs for repairing oxidative stress damage of myocardial cells.

[0016] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical solution or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical solution in the preparation of drugs for resisting myocardial cell apoptosis.

[0017] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical scheme or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical scheme in the preparation of a drug for repairing cardiac ischemia-reperfusion injury.

[0018] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical solution or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical solution in the preparation of drugs for inhibiting cardiac fibrosis.

[0019] The present invention provides an injectable hydrogel loaded with targeted engineered extracellular vesicles. The injectable hydrogel loaded with targeted engineered extracellular vesicles of the present invention has high stability, good biocompatibility, and adjustable mechanical properties, and can be injected into the pericardial cavity in a minimally invasive manner to form a cardiac patch and improve cardiac ischemia-reperfusion injury, and the injectable hydrogel loaded with targeted engineered extracellular vesicles (TeEV) of the present invention can regulate the release rate of targeted engineered extracellular vesicles in the hydrogel, thereby achieving the ability to continuously repair ischemia-reperfusion injury. The beneficial technical effects of the targeted engineered extracellular vesicle-loaded injectable hydrogel of the present invention include: (1) using fully biodegradable gelatin and natural extracellular vesicles as raw materials, there is no need to introduce other refractory compounds or inorganic materials for structural modification, and there is no need to add other toxic molecules or reagents, and it has good biocompatibility and body adaptability; (2) the injectable hydrogel system prepared by using simple synthetic GelMA hydrogel and extracellular vesicles is simple to operate, low in cost, and less time-consuming, and it is easy to achieve large-scale production for cardiac treatment; (3) the injectable hydrogel is injected into the pericardial cavity in a minimally invasive manner, and the pericardial cavity is used as a natural heart patch molding mold, thereby achieving a rapid and efficient treatment purpose. The TeEV-loaded GelMA hydrogel prepared by the present invention has good biocompatibility and body adaptability, and can have broad application prospects in multiple fields such as biomedical engineering and regenerative medicine.

[0020] In addition, the targeted engineered extracellular vesicle-loaded injectable hydrogel of the present invention is simple and convenient to use, has a significant therapeutic effect, and can be used to repair cardiac ischemia-reperfusion injury. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 For the Gelatin and GelMA provided by the present invention 1 H NMR spectrum;

[0023] Figure 2 The infrared spectra of Gelatin and GelMA provided by the present invention;

[0024] Figure 3 Transmission electron microscopy images of engineered EVs (eEVs) and targeted engineered EVs (TeEVs) provided by the present invention;

[0025] Figure 4 A release rate curve of TeEVs in hydrogel provided by the present invention;

[0026] Figure 5 Cell phagocytosis diagram of eEV and TeEV provided by the present invention;

[0027] Figure 6 The tunel dyeing diagram of NRCMs provided by the present invention;

[0028] Figure 7 The in vivo Masson staining image of the myocardium provided by the present invention;

[0029] Figure 8 This is an analysis chart of pathological related indicators of the myocardium in vivo provided by the present invention. DETAILED DESCRIPTION

[0030] The present invention provides an injectable hydrogel loaded with targeted engineered extracellular vesicles, wherein the injectable hydrogel loaded with targeted engineered extracellular vesicles (TeEV) is a GelMA hydrogel loaded with ischemia-targeted miR222 engineered extracellular vesicles; the ischemia-targeted miR222 engineered extracellular vesicles overexpress miR222, the sequence of which is: AGCUACAUCUGGCUACUGGGU (SEQ ID NO.2), and a surface-modified targeting polypeptide (cardiac targeting peptide (CTP)); the amino acid sequence of the targeting polypeptide is as shown in SEQ ID NO.1: Cys-Ser-Thr-Ser-Met-Leu-Lys-Ala-Cys. TeEV is encapsulated in mechanical hydrogels and injected in a minimally invasive manner to obtain a TeEV-loaded cardiac patch, thereby improving cardiac ischemia-reperfusion injury. TeEV precisely targets cardiomyocytes through injectable cardiac patches and rescues cell apoptosis caused by oxygen-glucose deprivation reperfusion stress (OGDR) overload in an efficient internalization manner. In addition, TeEV is continuously delivered to the myocardial infarction area to alleviate long-term cardiac dysfunction after cardiac remodeling.

[0031] In the present invention, the average Young's modulus of the targeted engineered extracellular vesicle-loaded injectable hydrogel is preferably 5 to 30 kPa, more preferably 14 to 18 kPa.

[0032] The present invention also provides a method for preparing the injectable hydrogel loaded with targeted engineered extracellular vesicles according to the above technical solution, comprising the following steps:

[0033] GelMA precursor was prepared using type A gelatin and methacrylic anhydride as raw materials;

[0034] Human umbilical cord mesenchymal stem cells are used as raw materials to extract and obtain HUC-MSC-derived extracellular vesicles; miR222 gene is transformed into HUC-MSC-derived extracellular vesicles to obtain miR222-engineered extracellular vesicles; the targeted peptide is mixed with DOPE-NHS solution to obtain a peptide linker, which is then concentrated and mixed with the miR222-engineered extracellular vesicles to obtain targeted engineered extracellular vesicles;

[0035] The GelMA precursor, the photoinitiator and the targeted engineered extracellular vesicles are mixed and loaded to obtain an injectable hydrogel loaded with the targeted engineered extracellular vesicles.

[0036] The present invention uses type A gelatin and methacrylic anhydride as raw materials to prepare a GelMA precursor. In the present invention, the preparation of the GelMA precursor preferably includes the following steps: dissolving type A gelatin in PBS to obtain a gelatin solution, and dropping methacrylic anhydride into the gelatin solution to react to obtain a GelMA precursor. In the present invention, type A gelatin is dissolved in PBS, preferably stirred at 40 to 60°C, more preferably at 50°C, and the stirring speed is preferably 300 to 500rpm, more preferably 400rpm, under which conditions, a uniform gelatin solution is obtained. In the present invention, in the gelatin solution, the concentration of type A gelatin is preferably 2.0 to 10.0wt%. After obtaining the gelatin solution, the present invention drops methacrylic anhydride into the gelatin solution for reaction. In the present invention, the mass ratio of type A gelatin to methacrylic anhydride is preferably 5g: (0.2 to 5) mL. By changing the grafting rate of the methacryloyl group, the hardness and adhesion of the GELMA hydrogel can be controlled, thereby synthesizing an injectable mechanical hydrogel. The surface morphology of GELMA hydrogel is a micro / nano graded porous structure. By changing the methacrylic anhydride content (such as 0.2mL, 1mL and 5mL), its structural morphology will also change accordingly, thereby changing the mechanical properties of the hydrogel (Young's modulus: 5-30kPa). When the mass ratio of type A gelatin to methacrylic anhydride is preferably 5g:1mL, the grafting rate of methacrylic acid groups is 52%, and the Young's modulus of the hydrogel is 14-18kPa. In the present invention, it is preferably added dropwise at 50°C and 400-600rpm, and the dropwise addition rate is preferably 0.5mL / min. In the present invention, the reaction conditions are preferably protected from light, stirred at 50°C (preferably 300-500rpm), and 3h. After stirring, it is preferably diluted with 5 times the volume of PBS. After dilution, the preferred dosage form of the present invention is dialyzed to remove the residual molecular monomers of MA. After dialysis, it is preferably filtered, sterilized, and freeze-dried to obtain a porous sponge-like GelMA precursor.

[0037] The present invention uses human umbilical cord mesenchymal stem cells as raw materials to extract HUC-MSC-derived extracellular vesicles; the miR222 gene is transformed into the HUC-MSC-derived extracellular vesicles to obtain miR222-engineered extracellular vesicles; the targeted polypeptide is mixed with a DOPE-NHS solution to obtain a peptide linker, which is then concentrated and mixed with the miR222-engineered extracellular vesicles to obtain targeted engineered extracellular vesicles. The present invention does not specifically limit the culture method of human umbilical cord mesenchymal stem cells, and conventional methods can be used for culture, such as in a solution containing 10% UltraGRO TM Serum Hydroclone TMMEMα modified culture medium is cultured in an incubator at 37°C and 5% CO2. The present invention does not specifically limit the method for extracting extracellular vesicles, and conventional differential centrifugation enrichment method can be used for collection. Specifically, preferably (1) centrifuge at 300g for 10 minutes at 4°C to collect the supernatant; (2) centrifuge at 2000g for 10 minutes at 4°C to collect the supernatant; (3) centrifuge at 10000g for 30 minutes at 4°C to collect the supernatant; (4) centrifuge at 100000g for 70 minutes at 4°C to collect the precipitate. The present invention does not specifically limit the method for transformation, and conventional gene transformation methods can be used, such as electroporation. The present invention does not specifically limit the electroporation method, and conventional conditions can be used to introduce genes by electroporation. In the present invention, the amino acid sequence of the targeting polypeptide is preferably as shown in SEQ ID NO.1: Cys-Ser-Thr-Ser-Met-Leu-Lys-Ala-Cys. The present invention preferably mixes the targeting peptide with a DOPE-NHS solution to prepare a peptide linker, which is then concentrated and mixed with extracellular vesicles to form targeted engineered extracellular vesicles (TeEV). More preferably, the present invention mixes 200 μL of a 3 μM targeting peptide with 50 μL of a 120 nM DOPE-NHS solution for 1 h to prepare a peptide linker, which is then concentrated and mixed with 1×10 9 The extracellular vesicles were mixed at 4°C for 1 hour to form targeted engineered extracellular vesicles.

[0038] After obtaining the GelMA precursor and the targeted engineered extracellular vesicles, the present invention mixes the GelMA precursor, the photoinitiator and the targeted engineered extracellular vesicles for loading to obtain an injectable hydrogel loaded with the targeted engineered extracellular vesicles. In the present invention, during the loading process, PBS is preferably used as a solvent to prepare the reaction solution, and the weight ratio of the GelMA precursor to the photoinitiator in the reaction solution is preferably (2 to 8):100, more preferably 5:100, and each 20 μL reaction solution preferably contains 1×10 targeted engineered extracellular vesicles. 8 ~5×10 9 , more preferably 1×10 9 More preferably, the mass percentage of the GelMA precursor in the reaction solution is preferably 10%, and the mass percentage of the photoinitiator is preferably 0.5%.

[0039] The present invention does not specifically limit the source of the raw materials used in the preparation process of the injectable hydrogel loaded with targeted engineered extracellular vesicles, and conventional commercially available products or commissioned companies can be used for synthesis. The GelMA hydrogel precursor described in the present invention is prepared by reacting type A gelatin and methacrylic anhydride, and the hydrogel is loaded with targeted engineered extracellular vesicles, and the mechanical properties of the hydrogel are controlled by the methacrylic anhydride content. The GelMA hydrogel synthesized and prepared by the present invention has good stability and can be stored for a long time, and there is no obvious change in structure and function after being stored for more than half a year.

[0040] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical solution or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical solution in the preparation of a drug for repairing oxidative stress damage to myocardial cells. Myocardial cells damaged by oxidative stress have a high uptake capacity for the targeted engineered extracellular vesicles in the targeted engineered extracellular vesicle-loaded injectable hydrogel of the present invention.

[0041] The present invention also provides the use of the injectable hydrogel loaded with targeted engineered extracellular vesicles described in the above technical solution or the injectable hydrogel loaded with targeted engineered extracellular vesicles prepared by the preparation method described in the above technical solution in the preparation of drugs for resisting myocardial cell apoptosis. In situ injection of the injectable hydrogel loaded with targeted engineered extracellular vesicles can quickly release the targeted engineered extracellular vesicles in the early stage, and the targeted engineered extracellular vesicles are targetedly endocytosed into damaged myocardial cells, thereby achieving the improvement of the anti-apoptosis ability of myocardial cells.

[0042] The present invention also provides the use of the injectable hydrogel loaded with targeted engineered extracellular vesicles described in the above technical solution or the injectable hydrogel loaded with targeted engineered extracellular vesicles prepared by the preparation method described in the above technical solution in the preparation of a drug for repairing cardiac ischemia-reperfusion injury. The injectable hydrogel loaded with targeted engineered extracellular vesicles of the present invention can achieve sustained release and chronic cardiac ischemia-reperfusion repair. Specifically, the injectable hydrogel loaded with targeted engineered extracellular vesicles of the present invention can significantly improve cardiac IRI remodeling through left ventricular ejection fraction (EF) and shortening fraction (FS), reduce the level of cardiac fibrosis, inhibit the expression of pathological genes, improve cardiac IRI remodeling, and prevent the expression of inflammatory factors, and reverse the inflammatory response in IR remodeling. Implanting GEL-TeEV to form a patch through in situ minimally invasive injection can inhibit the process of cardiac fibrosis and protect pathological cardiac IRI remodeling, thereby improving cardiac function.

[0043] The present invention also provides the use of the targeted engineered extracellular vesicle-loaded injectable hydrogel described in the above technical solution or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method described in the above technical solution in the preparation of drugs for inhibiting cardiac fibrosis.

[0044] The targeted engineered extracellular vesicle-loaded injectable hydrogel of the present invention can be used for the treatment of cardiac ischemia-reperfusion injury. The targeted engineered extracellular vesicle-loaded injectable hydrogel of the present invention can be injected to synthesize a cardiac patch. The synthesis process of the present invention is simple and low in cost. At the same time, the prepared cardiac patch has good biocompatibility and can be widely used in technical fields such as cardiac microfluidic systems and biomedical engineering. Specifically, the photoinitiator triggers photocrosslinking to prepare the GelMA hydrogel, and the GelMA precursor and the photoinitiator are uniformly dissolved in PBS containing TeEV and crosslinked under 405 nanometer ultraviolet light to form a TeEV-loaded injectable hydrogel cardiac patch for improving cardiac ischemia-reperfusion injury. The present invention preferably applies the targeted engineered extracellular vesicle-loaded injectable hydrogel to the pericardial cavity through an injection drop coating process with a 20 μL syringe, preferably drop coating to the damaged heart area, thereby improving cardiac function, accurately targeting myocardial cells to alleviate acute ischemia-reperfusion injury and reverse long-term cardiac dysfunction after cardiac remodeling.

[0045] In order to further illustrate the present invention, a targeted engineered extracellular vesicle-loaded injectable hydrogel, a preparation method and an application thereof provided by the present invention are described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0046] Example 1

[0047] A method for preparing an injectable hydrogel precursor, the specific preparation method is as follows:

[0048] First, methacryloyl groups were introduced into the type A gelatin chain to design and synthesize the viscoelastic GelMA precursor. Specifically, 5 g of type A gelatin powder (9000-70-8, Sigma-Aldrich) was completely dissolved in 90 mL of phosphate buffered saline (PBS, pH = 7.6) and stirred at 400 rpm at 50 ° C to prepare a uniform gelatin solution. Then, 0.2 mL of methacrylic anhydride (760-93-0, Aladdin) was added to the above gelatin solution and stirred at 400 rpm at 50 ° C, with the drop rate set to 0.5 mL / min to synthesize the GelMA precursor. The mixed solution was reacted in the dark for 3 hours, stirred at 50 ° C, and further diluted with 5 times the volume of PBS. Subsequently, the residual molecular monomers of MA were removed by dialyzing for 5 days using a dialysis tube cellulose membrane (molecular weight of 14 kD), and ultrapure water was replaced 3 times a day. The filtrate was filtered through a 0.22 μm filter membrane, and the GelMA precursor solution was sterilized and freeze-dried for 3 days to obtain a porous sponge-like GelMA precursor.

[0049] The average grafting rate of methacrylic acid groups in type A gelatin of the hydrogel precursor prepared in Example 1 is 25%. In addition, after adding a photoinitiator to induce the curing of the hydrogel precursor, the average Young's modulus of GelMA prepared in Example 1 is 5 kPa, specifically, the Young's modulus ranges from 3 to 8 kPa.

[0050] Example 2

[0051] A method for preparing an injectable hydrogel precursor, the specific preparation method is as follows:

[0052] First, methacryloyl groups were introduced into the type A gelatin chain to design and synthesize the viscoelastic GelMA precursor. Specifically, 5 g of type A gelatin powder (9000-70-8, Sigma-Aldrich) was completely dissolved in 90 mL of phosphate buffered saline (PBS, pH = 7.6) and stirred at 400 rpm at 50 ° C to prepare a uniform gelatin solution. Then, 1 mL of methacrylic anhydride was added to the above gelatin solution and stirred at 400 rpm at 50 ° C, with the drop rate set to 0.5 mL / min to synthesize the GelMA precursor. The mixed solution was reacted in the dark for 3 hours, stirred at 50 ° C, and further diluted with 5 times the volume of PBS. Subsequently, the residual molecular monomers of MA were removed by dialyzing using a dialysis tube cellulose membrane (molecular weight of 14 kD) for 5 days, and ultrapure water was replaced 3 times a day. The filtrate was filtered through a 0.22 μm filter membrane, and the GelMA precursor solution was sterilized and freeze-dried for 3 days to obtain a porous sponge-like GelMA precursor.

[0053] The GelMA precursor was successfully prepared by 1H-NMR analysis, Figure 1 The existence of the grafted conjugated structure of methacryloyl was confirmed. For the synthesized GelMA precursor, the proton peak δ value of methacrylate vinyl increased at 5.4ppm and 5.7ppm, while the proton peak of methylene lysine decreased at 2.9ppm, indicating that the modification of methacrylic acid groups in type A gelatin chains increased, and the average grafting rate was 52%. Infrared spectroscopy was used to characterize type A gelatin and GelMA precursor ( Figure 2 The GelMA spectrum shows the typical characteristic peaks of gelatin chains, with OH and NH contraction vibration peaks at 3292 cm -1 The NH contraction peak is at 1544 cm -1 The CN contraction peak and NH bending peak are at 1237 cm -1 In particular, in the GelMA spectrum, around 1631 cm -1 The characteristic peak at is the C=C contraction peak of the methacrylate group. In addition, after adding a photoinitiator to induce the curing of the hydrogel precursor, the average Young's modulus of the GelMA hydrogel prepared in Example 2 is 15 kPa, and specifically, the Young's modulus ranges from 14 to 18 kPa.

[0054] Example 3

[0055] A method for preparing an injectable hydrogel precursor, the specific preparation method is as follows:

[0056] First, methacryloyl groups were introduced into the type A gelatin chain to design and synthesize the viscoelastic GelMA precursor. Specifically, 5 g of type A gelatin powder was completely dissolved in 90 mL of phosphate buffered saline (PBS, pH = 7.6) and stirred at 400 rpm at 50 ° C to prepare a uniform gelatin solution. Then, 5 mL of methacrylic anhydride was added to the above gelatin solution and stirred at 400 rpm at 50 ° C, with the drop rate set to 0.5 mL / min to synthesize the GelMA precursor. The mixed solution was reacted in the dark for 3 hours, stirred at 50 ° C, and further diluted with 5 times the volume of PBS. Subsequently, the residual molecular monomers of MA were removed by dialyzing for 5 days using a dialysis tube cellulose membrane (molecular weight of 14 kD), and ultrapure water was replaced 3 times a day. The filtrate was filtered with a 0.22 μm filter membrane, the GelMA precursor solution was sterilized, and freeze-dried for 3 days to obtain a porous sponge-like GelMA precursor.

[0057] The grafting rate of methacrylic acid groups in type A gelatin of the hydrogel precursor prepared in Example 3 was 91%. In addition, after adding a photoinitiator to induce the curing of the hydrogel precursor, the average Young's modulus of the GelMA hydrogel prepared in Example 3 was 30 kPa, and specifically, the Young's modulus ranged from 25 to 35 kPa.

[0058] Example 4

[0059] A method for preparing engineered extracellular vesicles targeting cardiac ischemia-reperfusion, the specific implementation method is as follows:

[0060] Human umbilical cord mesenchymal stem cells (HUC-MSCs) were cultured in 10% UltraGRO TM Serum Hydroclone TM MEMα modified culture medium (SH30265.01 Hyclone) was cultured in a 37°C and 5% CO2 incubator. The supernatant of HUC-MSCs was collected by a four-step differential centrifugation enrichment method using an Optima XPN-100 ultracentrifuge to obtain EVs: (1) centrifuge at 300g for 10 min at 4°C to collect the supernatant; (2) centrifuge at 2000g for 10 min at 4°C to collect the supernatant; (3) centrifuge at 10000g for 30 min at 4°C to collect the supernatant; (4) centrifuge at 100000g for 70 min at 4°C to collect the precipitate. The deposited extracellular vesicles were obtained for further experiments. The miR222 gene was transferred into HUC-MSC-derived extracellular vesicles by electroporation to establish miR222-engineered extracellular vesicles. In addition, ischemia-targeted peptides (sequence code: Cys-Ser-Thr-Ser-Met-Leu-Lys-Ala-Cys, commissioned by Qiangyao Biotechnology Co., Ltd. for synthesis) were combined with miR222-engineered extracellular vesicles to form ischemia-targeted miR222-engineered EVs (TeEVs). Specifically, 200 μL of 3 μM targeting peptides were mixed with 50 μL of 120 nM DOPE-NHS solution for 1 h to prepare peptide linkers, which were then concentrated and mixed with 1×10 9 The extracellular vesicles were mixed at 4°C for 1 h to form targeted engineered extracellular vesicles (TeEVs).

[0061] EVs secreted by HUC-MSCs were isolated by differential centrifugation, engineered by electroporation to overexpress miR222, and targeted by cardiac ischemia targeting peptide (CSTSMLKAC) to form ischemia-targeted miR222-engineered EVs. miR222-engineered EVs overexpressed miR222 RNA 150-fold higher than control EVs. The spherical structure and size of eEV and TeEV nanoparticles were observed using transmission electron microscopy (TEM), and their sizes were calculated to be approximately 80-130 nm ( Figure 3 ). TeEVs were successfully designed and prepared by introducing the CSTSMLKAC peptide targeting cardiac ischemia into miR222-engineered EVs.

[0062] Example 5

[0063] The method of the cardiac ischemia-reperfusion injury model, the specific implementation scheme is as follows:

[0064] The method for constructing a cardiac ischemia-reperfusion injury model includes the following specific implementation steps: first, subjecting the heart to 30 minutes of ischemia and then reperfusing blood for 3 weeks to construct an ischemia-reperfusion injury (IRI) model (abbreviated as IRI or IRI+3W).

[0065] The method for using TeEV to repair cardiac ischemic reperfusion injury, the specific implementation scheme is as follows:

[0066] TeEV-based cardiac ischemia-reperfusion injury repair, specifically, 20 μL sterile PBS containing 1×10 9 By in situ injection, 20 μL of 1×10 TeEVs were injected into 9 TeEV PBS solution was injected into the damaged heart area to treat cardiac ischemia-reperfusion injury, which corresponds to the TeEV group in the following text.

[0067] The method for using injectable hydrogel to repair cardiac ischemic reperfusion injury, the specific implementation scheme is as follows:

[0068] Based on the GelMA hydrogel prepared in Example 2, a photoinitiator was introduced into the GelMA precursor to prepare the GelMA hydrogel by photocrosslinking synthesis. Specifically, 10% (weight fraction) of the GelMA precursor and 0.5% of the photoinitiator (LAP405 nm) were uniformly dissolved in 20 μL of sterile PBS. 20 μL of the hydrogel solution was injected into the damaged heart area by in situ injection, and crosslinked under 405 nm ultraviolet light for 20 seconds to form a hydrogel heart patch, corresponding to the GEL group in the following text.

[0069] The preparation method of TeEV-loaded injectable hydrogel for treating cardiac ischemia-reperfusion injury is as follows:

[0070] The preparation of TeEV-loaded GelMA hydrogel was used for the repair of cardiac ischemic reperfusion injury. A photoinitiator was introduced into the GelMA precursor, and the GelMA hydrogel was prepared by photocrosslinking synthesis. Specifically, the TeEV prepared in Example 4 was added to sterile PBS to obtain TeEV sterile PBS, and then 10% (weight percentage) of the GelMA precursor prepared in Example 2 and 0.5% of the photoinitiator (LAP 405nm) were uniformly dissolved in 20 μL of TeEV sterile PBS. By in situ injection, 20 μL of 1×10 9 The TeEV hydrogel solution was injected into the damaged heart area and cross-linked under 405nm UV light for 20s to form a TeEV-loaded hydrogel heart patch.

[0071] TeEV was loaded into GelMA hydrogel (obtaining GEL-TeEV hydrogel), and the mechanical properties, TeEV release rate and biocompatibility of GEL-TeEV hydrogel were investigated. The average Young's modulus of the GEL-TeEV sample tested by atomic force microscopy was about 14-18 kPa, which was the same as the result of the hydrogel sample in Example 2, indicating that the addition of TeEV did not affect the mechanical properties of the cross-linked GelMA hydrogel. The hydrogel loaded with TeEV was prepared into a cylinder with a diameter of 8 mm and a height of 3 mm, and placed in 1 mL of PBS solution. 20 uL of PBS supernatant was taken, and the TeEV content in the supernatant was calculated using a nanoparticle tracer analyzer to determine its sustained release performance in the hydrogel. The TeEV release curve increased with the increase of release time, and the TeEV release amount accumulated to 70% within 72 hours. Subsequently, stable and controllable release of TeEV can be achieved within 3 weeks ( Figure 4 ). Due to the in situ injection cross-linking properties of GelMA precursor and TeEVs in the pericardial cavity photoinitiator, cardiomyocytes will be covered under the GelMA hydrogel to simulate the in vivo cellular microenvironment. The biocompatibility of the cross-linked hydrogel was studied. The cells were cultured in 24-well plates, GEL-TeEV was added and solidified, and the cells in the synthetic hydrogel showed high survival ability and excellent biocompatibility (survival rate of more than 90%) through CCK-8 detection. Based on the adjustable mechanical properties, controllable release rate and biocompatibility of the hydrogel, TeEV-loaded mechanical hydrogel was prepared and used as an injectable heart patch in the pericardial cavity, thereby achieving protection of cardiac function and repair of cardiac damage.

[0072] Myocardial cell oxidative stress injury test

[0073] The targeted uptake ability of TeEVs in neonatal rat cardiomyocytes (NRCMs) was evaluated by fluorescence labeling assay. The uptake results showed that more red targeted engineered extracellular vesicles (ETVs) were observed in the miR222EV+CTP (TeEV) group compared with the PBS and non-targeted miR222 EV (eEV) groups. Figure 5 ). Under OGD / R conditions, the red fluorescence in the cells of the TeEV group was enhanced, indicating excellent targeted uptake ability.

[0074] In order to verify the targeted repair ability of GEL-TeEV in damaged NRCMs, Tunel staining was used to monitor its ability to rescue NRCMs from apoptosis under OGD / R stress ( Figure 6). Compared with PBS and GEL controls under OGD / R stress conditions, the number of Tunel-positive cells was significantly reduced after treatment with TeEV and GEL-TeEV. In addition, the ratio of tunel-positive cells was calculated to consider the quantitative results, and the results showed a reduced level of apoptosis, revealing that TeEV and GEL-TeEV have the ability to alleviate cell apoptosis after NRCMs are damaged by OGDR, and GEL-TeEV can achieve the slow release of TeEV in the hydrogel to achieve the purpose of long-term treatment. The apoptosis-related proteins of Bax, Bcl2, cleaved Caspase3 and Caspase3 were analyzed by Western blotting (WB) and showed reduced expression levels. This result indicates that the in situ injected GEL-TeEV hydrogel can quickly release TeEV in the early stage and be targeted and internalized into damaged NRCMs to achieve high uptake capacity and anti-apoptosis ability in NRCMs under OGD / R stress. In addition, TeEV in GEL-TeEV can be slowly released within 3 weeks, thereby treating NRCMs under long-term OGD / R stress.

[0075] The above results show that injectable hydrogels loaded with TeEV have a repairing effect on cardiomyocyte oxidative stress damage (OGDR). Moreover, TeEV in hydrogels can achieve long-term therapeutic effects within 3 weeks.

[0076] In vivo cardiac ischemia-reperfusion repair assay

[0077] Targeted engineered extracellular vesicles were encapsulated in GelMA hydrogels, and TeEV was injected to achieve the purpose of sustained release and chronic cardiac ischemia-reperfusion repair. The ischemia-reperfusion injury (IRI) model was constructed by 30 minutes of cardiac ischemia and then reperfusion of blood. The heart subjected to long-term reperfusion for 3 weeks was repaired by injection of GEL-TeEV hydrogel (IRI+GEL-TeEV). In addition, the ischemia-reperfusion injury group was injected with PBS as a control group (IRI+PBS), and two other control groups were set up, IRI+GEL and IRI+TeEV. The ischemia-reperfusion injury group was injected with GEL as the IRI+GEL control group, and the ischemia-reperfusion injury group was injected with TeEV as the IRI+TeEV control group. Cardiac ultrasound showed that compared with the left ventricular ejection fraction (EF, 36.51±3.07%) and shortening fraction (FS, 21.81±2.20%) of the IRI+PBS control group, the EF (67.46±4.15%) and FS (45.36±3.89%) of GEL-TeEVs were significantly improved, thereby improving cardiac IRI remodeling. Masson staining was used to evaluate the level of cardiac fibrosis after GEL-TeEV treatment ( Figure 7). Moreover, the experiment was conducted on the group that did not undergo cardiac ischemia-reperfusion injury and was regarded as the sham operation (Sham) group. Compared with the sham operation group (1.05±0.68%), the fibrosis area in the IRI model (19.28±2.63%) was significantly increased, the cardiac fibrosis levels in the GEL group (17.03±3.32%) and the TeEV group (10.56±1.23%) were reduced, and the fibrosis level in the GEL-TeEV injection transplantation (6.63±1.24%) was significantly reduced. In the IRI 3W+PBS model, the pathological cardiac genes of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and β-MHC were significantly increased, while the GEL group and TeEV group, although they could improve the expression of pathological-related genes, had limited ability to repair the heart, and the pathology-mediated gene expression was significantly inhibited by GEL-TeEV therapy to improve cardiac IRI remodeling, thereby achieving repair of the pathological heart ( Figure 8 ). Therefore, the GEL-TeEV patch implanted by in situ minimally invasive injection can inhibit the progression of cardiac fibrosis and protect pathological cardiac IRI remodeling, thereby improving cardiac function.

[0078] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creative work, and these embodiments all fall within the scope of protection of the present invention.

Claims

1. A targeted engineered extracellular vesicle-loaded injectable hydrogel, characterized in that: The injectable hydrogel loaded with targeted engineered extracellular vesicles is a GelMA hydrogel loaded with ischemia-targeted miR222 engineered extracellular vesicles; the ischemia-targeted miR222 engineered extracellular vesicles overexpress miR222 and are surface-modified with targeting polypeptides; the amino acid sequence of the targeting polypeptide is shown in SEQ ID NO.

1.

2. The injectable hydrogel according to claim 1, characterized in that The average Young's modulus of the injectable hydrogel loaded with the targeted engineered extracellular vesicles is 5 to 30 kPa.

3. The method for preparing the targeted engineered extracellular vesicle-loaded injectable hydrogel according to claim 1 or 2, comprising the following steps: GelMA precursor was prepared using type A gelatin and methacrylic anhydride as raw materials; Human umbilical cord mesenchymal stem cells are used as raw materials to extract and obtain HUC-MSC-derived extracellular vesicles; miR222 gene is transformed into HUC-MSC-derived extracellular vesicles to obtain miR222-engineered extracellular vesicles; the targeted peptide is mixed with DOPE-NHS solution to obtain a peptide linker, which is then concentrated and mixed with the miR222-engineered extracellular vesicles to obtain targeted engineered extracellular vesicles; The GelMA precursor, the photoinitiator and the targeted engineered extracellular vesicles are mixed and loaded to obtain an injectable hydrogel loaded with the targeted engineered extracellular vesicles.

4. The preparation method according to claim 3, characterized in that: The preparation of GelMA precursor includes the following steps: Type A gelatin was dissolved in PBS to obtain a gelatin solution, and methacrylic anhydride was added dropwise to the gelatin solution to react to obtain a GelMA precursor.

5. The preparation method according to claim 3 or 4, characterized in that: The mass ratio of type A gelatin to the volume of methacrylic anhydride is 5 g: (0.2-5) mL.

6. The preparation method according to claim 3, characterized in that: During the loading process, PBS was used as a solvent to prepare a reaction solution, the weight ratio of GelMA precursor to photoinitiator was (2-8):100, and each 20 μL reaction solution contained 1×10 targeted engineered extracellular vesicles. 8 ~5×10 9 indivual.

7. Use of the targeted engineered extracellular vesicle-loaded injectable hydrogel according to claim 1 or 2 or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method according to any one of claims 3 to 6 in the preparation of a drug for repairing oxidative stress damage to myocardial cells.

8. Use of the targeted engineered extracellular vesicle-loaded injectable hydrogel according to claim 1 or 2 or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method according to any one of claims 3 to 6 in the preparation of drugs for preventing cardiomyocyte apoptosis.

9. Use of the targeted engineered extracellular vesicle-loaded injectable hydrogel according to claim 1 or 2 or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method according to any one of claims 3 to 6 in the preparation of a drug for repairing cardiac ischemia-reperfusion injury.

10. Use of the targeted engineered extracellular vesicle-loaded injectable hydrogel according to claim 1 or 2 or the targeted engineered extracellular vesicle-loaded injectable hydrogel prepared by the preparation method according to any one of claims 3 to 6 in the preparation of drugs for inhibiting cardiac fibrosis.

Citation Information

Patent Citations

  • Construction of MicroRNA gene mediated novel tissue engineered nerves and application of MicroRNA genes in nerve defect repair

    CN106474549A

  • Pharmaceutical carriers containing mirnas for use in the treatment of fibrotic diseases caused by hyperglycemia

    CN109195637A

  • GelMA hydrogel as well as preparation method and application thereof

    CN117138110A

  • MiRNA combinations for prevention and treatment of cancer

    CN118103509A

  • Engineered extracellular vesicle composition for targeted therapy of injured myocardium and application of engineered extracellular vesicle composition

    CN118416022A